A previous study revealed that venetoclax plus azacitidine improved remission rates, but not DOR or OS, compared with azacitidine alone in patients with TP53-mutated MDS with high-risk cytogenetics (26). This evidence concerns the gene TP53 and myelodysplastic syndrome.